These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37739241)

  • 1. Antibiotic Resistance Patterns Among Uropathogens in Female Outpatients Affected by Uncomplicated Cystitis: Focus on Fosfomycin Trometamol.
    Cai T; Verze P; Arcaniolo D; Pandolfo SD; Smarrazzo F; Manfredi C; Tascini C; Caciagli P; Lanzafame M; De Sio M; Wagenlehner F; Johansen TEB; Palmieri A
    Int J Antimicrob Agents; 2023 Nov; 62(5):106974. PubMed ID: 37739241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro activity of fosfomycin trometamol in the treatment of Escherichia coli related uncomplicated urinary tract infections].
    Hoşbul T; Ozyurt M; Baylan O; Bektöre B; Ardiç N; Ceylan S; Erdemoğlu A; Haznedaroğlu T
    Mikrobiyol Bul; 2009 Oct; 43(4):645-9. PubMed ID: 20084918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SUsceptibility and Resistance to Fosfomycin and other antimicrobial agents among pathogens causing lower urinary tract infections: findings of the SURF study.
    Tutone M; Bjerklund Johansen TE; Cai T; Mushtaq S; Livermore DM
    Int J Antimicrob Agents; 2022 May; 59(5):106574. PubMed ID: 35307561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficiency of fosfomycin trometamol for treatment of acute uncomplicated cystitis].
    Kuzmenko AV; Kuzmenko VV; Gyaurgiev TA
    Urologiia; 2018 Dec; (6):70-75. PubMed ID: 30742381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience of using the antibacterial drug Fosfomycin Esparma for the treatment of acute uncomplicated cystitis in women].
    Aboyan IA; Orlov YN; Voloshina OA; Orlov NV; Pavlov DS
    Urologiia; 2019 Sep; (4):20-25. PubMed ID: 31535800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fosfomycin susceptibility of urinary Escherichia coli isolates producing extended-spectrum beta-lactamase according to CLSI and EUCAST recommendations].
    Cağan Aktaş S; Gençer S; Batırel A; Hacıseyitoğlu D; Ozer S
    Mikrobiyol Bul; 2014 Oct; 48(4):545-55. PubMed ID: 25492650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fosfomycin trometamol: a review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria.
    Keating GM
    Drugs; 2013 Nov; 73(17):1951-66. PubMed ID: 24202878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro susceptibility of Escherichia coli strains isolated from urine samples obtained in mainland China to fosfomycin trometamol and other antibiotics: a 9-year surveillance study (2004-2012).
    Lai B; Zheng B; Li Y; Zhu S; Tong Z
    BMC Infect Dis; 2014 Feb; 14():66. PubMed ID: 24502648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Fosfomycin against Extended-Spectrum-β-Lactamase-Producing Uropathogens in Patients in the Community and Hospitalized Patients.
    Linsenmeyer K; Strymish J; Weir S; Berg G; Brecher S; Gupta K
    Antimicrob Agents Chemother; 2016 Feb; 60(2):1134-6. PubMed ID: 26596940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A
    Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?
    Knottnerus BJ; Nys S; Ter Riet G; Donker G; Geerlings SE; Stobberingh E
    J Antimicrob Chemother; 2008 Aug; 62(2):356-9. PubMed ID: 18424789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study Over a Period of 12 Years.
    Aris P; Boroumand MA; Rahbar M; Douraghi M
    Microb Drug Resist; 2018 Jun; 24(5):607-612. PubMed ID: 29064348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fosfomycin: an underrated antibiotic for urinary tract infections due to Escherichia coli].
    Garau M; Latorre A; Alonso-Sanz M
    Enferm Infecc Microbiol Clin; 2001 Dec; 19(10):462-6. PubMed ID: 11844449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary Tract Infections among Indonesian Pregnant Women and Its Susceptibility Pattern.
    Rosana Y; Ocviyanti D; Halim M; Harlinda FY; Amran R; Akbar W; Billy M; Akhmad SRP
    Infect Dis Obstet Gynecol; 2020; 2020():9681632. PubMed ID: 32372856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.
    Ungheri D; Albini E; Belluco G
    J Chemother; 2002 Jun; 14(3):237-40. PubMed ID: 12120876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline.
    Garau J
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():198-202. PubMed ID: 18154548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in health care-associated urinary tract infection: focus on susceptibility to fosfomycin.
    Cho YH; Jung SI; Chung HS; Yu HS; Hwang EC; Kim SO; Kang TW; Kwon DD; Park K
    Int Urol Nephrol; 2015 Jul; 47(7):1059-66. PubMed ID: 26026972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.